Entrada Therapeutics Enhances Workforce with New Stock Grants
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a Boston-based biopharmaceutical company, has announced a significant move to strengthen its team by granting 23,820 restricted stock units (RSUs) to recently hired non-executive employees. This decision aligns with the company’s ongoing commitment to attract talented individuals and was made effective as of June 1, 2025. The grants were approved by the Compensation Committee of the Board of Directors, following the regulations set forth by Nasdaq Listing Rule 5635(c)(4).
Details of the Inducement Plan
The structure of the RSUs is designed with a clear vesting schedule to encourage long-term commitment from the new employees. Specifically, one-fourth of the RSUs will vest on the one-year anniversary of the vesting commencement date, while the remaining units will vest incrementally at a rate of 6.25% quarterly. The scheduled vesting dates are set for March 1, June 1, September 1, and December 1 of each following year, contingent on each employee maintaining continuous service with the company.
About Entrada Therapeutics
Founded with the mission to revolutionize the treatment landscape, Entrada Therapeutics focuses on the development of a unique class of biopharmaceuticals aimed at delivering therapies to previously unreachable intracellular targets. Utilizing its proprietary Endosomal Escape Vehicle (EEV™) technology, Entrada’s innovative approach enables efficient delivery of various treatments across organs and tissues, enhancing their therapeutic potential.
Advancing Therapeutic Development
Entrada Therapeutics is advancing an impressive pipeline of programs targeting neuromuscular and ocular diseases. Among its lead programs is an oligonucleotide development initiative that aims to provide treatments for Duchenne muscular dystrophy patients eligible for specific exon skipping therapies (44, 45, 50, and 51). Furthermore, the company is also involved in partnerships to push forward clinical-stage treatments such as VX-670 for myotonic dystrophy type 1.
Company Information
For those interested in learning more about the cutting-edge research and innovative solutions at Entrada Therapeutics, additional information is available on the company’s official website. Visitors can also connect with Entrada on social media platforms like LinkedIn to stay updated on the latest developments and opportunities within the company.
Contacting Entrada Therapeutics
For media inquiries or further information, interested parties can reach out to Karla MacDonald, the Chief Corporate Affairs Officer at Entrada Therapeutics. She is available via email for discussions regarding the company’s latest initiatives and future prospects.
Frequently Asked Questions
What are the restricted stock units (RSUs) granted by Entrada Therapeutics?
The RSUs are stock options given to new employees as an incentive, which vest over time based on continued employment with the company.
When do the RSUs vest?
The vesting schedule includes one-fourth of the RSUs vesting after one year, with subsequent portions vesting quarterly.
What is the goal of Entrada Therapeutics?
Entrada Therapeutics aims to develop transformative therapies that target previously unreachable intracellular mechanisms to treat various diseases.
What is the EEV™ technology?
EEV™ technology is Entrada Therapeutics' proprietary method for efficiently delivering therapeutics into cells, improving treatment outcomes.
Who can be contacted for media inquiries?
Karla MacDonald, the Chief Corporate Affairs Officer, is the primary contact for media and investor relations at Entrada Therapeutics.
